The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients

J Cai, J Ribkoff, S Olson… - European journal of …, 2020 - Wiley Online Library
Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric
complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes …

Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care

H Al-Samkari - Blood, The Journal of the American Society of …, 2021 - ashpublications.org
Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the
emergence and development of antiangiogenic therapies to eliminate bleeding …

Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia

ME Faughnan, JJ Mager, SW Hetts… - Annals of internal …, 2020 - acpjournals.org
Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant
disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of …

[HTML][HTML] An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

H Al-Samkari, RS Kasthuri, JG Parambil… - …, 2021 - ncbi.nlm.nih.gov
Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare
multisystem vascular disorder that causes chronic gastrointestinal bleeding, epistaxis, and …

[HTML][HTML] A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies

H Al‐Samkari, W Eng - Journal of Thrombosis and Haemostasis, 2022 - Elsevier
Vascular anomalies represent a diverse group of disorders classified broadly as
malformations or tumors and include the second most common hereditary bleeding disorder …

Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial

S Dupuis‐Girod, S Rivière, C Lavigne… - Journal of Internal …, 2023 - Wiley Online Library
Background Bevacizumab—a humanized monoclonal antibody—has been widely used to
treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has …

European Reference Network for Rare Vascular Diseases (VASCERN): when and how to use intravenous bevacizumab in hereditary haemorrhagic telangiectasia …

S Dupuis-Girod, CL Shovlin, AD Kjeldsen… - European Journal of …, 2022 - Elsevier
Hereditary haemorrhagic telangiectasia (HHT) is a rare vascular multisystemic disease that
leads to epistaxis, anaemia due to blood loss, and arteriovenous malformations (AVMs) in …

Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia

JG Parambil, JR Gossage, KR McCrae, TD Woodard… - Angiogenesis, 2022 - Springer
Hereditary hemorrhagic telangiectasia (HHT) is a rare angiogenic disorder causing chronic
gastrointestinal bleeding, epistaxis, and severe anemia. Pazopanib is an oral multi-kinase …

Treatments of epistaxis in hereditary hemorrhagic telangiectasia: Systematic review and network meta-analysis

W Chitsuthipakorn, MP Hoang… - Current allergy and …, 2023 - Springer
Abstract Purpose of Review To analyze and compare the effects of epistaxis treatments for
Hereditary Hemorrhagic Telangiectasia (HHT) patients. Recent Findings Of total of 21 …

[HTML][HTML] Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy

N Watson, H Al‐Samkari - Journal of Thrombosis and Haemostasis, 2021 - Elsevier
Over the past two decades, therapies targeting angiogenesis have developed into a major
class of cancer therapeutics. The vascular endothelial growth factor (VEGF) family of …